Search company, investor...

Predict your next investment

Axxam company logo
Corporation
HEALTHCARE | Biotechnology
axxam.com

Investments

1

Partners & Customers

10

About Axxam

Axxam is a science-driven biotechnology company that offers early-stage discovery research services for the life science industry. It is a provider of integrated discovery services across Life Sciences industries including pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food, and beverages. The company was founded in 2001 and is based in Bresso, Italy.

Headquarters Location

Via Meucci, 3

Bresso, 20091,

Italy

Want to inform investors similar to Axxam about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Axxam News

Hypoxia Market Has Exploded: Opportunities & Challenges in Near Future with Key Players like CASI Pharmaceuticals Inc, Spotlight Labs,LLC, F.Hoffmann-La Roche Ltd, AXXAM S.p.A.

Feb 18, 2021

. Hypoxia market is a condition in which the body does not get enough oxygen for supply and oxygen therapy is provided in the complete absence of oxygen, so that the tissue can get oxygen in sufficient manner. It is diagnosed by physical examination and by using oxygen monitors, which are also known as pulse oximeters. It is used in various applications such as in hospitals, specialty clinics. Hypoxia market estimated to register substantial CAGR in the forecast period of 2019 to 2026. The report contains data for historic year 2017 and the base year of calculation is 2018. The growth of the market can be attributed to the strategic initiatives by the market players. This Hypoxia Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry. The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market. This Hypoxia Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. To Get This Report at 30% Discount, Click Here Growing investment in R&D expenditure is boosting the market in the forecast period Rising prevalence of hypoxic condition will propel the growth of the market Technological advancement is also fueling the market growth Availability of substitute in the market is hampering the market growth Strict government regulation will also restraint the market in the forecast period Availability of nutrients and eating fish can reduce hypoxia which may hinder the market growth The major players covered in the Hypoxia Market Some of the major companies functioning in global hypoxia market are Aileron Therapeutics, Inc., CASI Pharmaceuticals Inc, Spotlight Labs,LLC, F.Hoffmann-La Roche Ltd, AXXAM S.p.A, HypOxygen, Oncolmmune, Nasdaq,Inc, Hancock Medical Inc, Phio Pharmaceuticals, International Marketers For Scientific Equipments & Technologies, Coy Laboratory Products, Inc, Thermo Fisher Scientific, Baker, STEMCELL Technologies Inc, Bioxia, Hypxico Europe, Merck KGaA among others. Major TOC Of The Report Chapter One: Hypoxia Market Overview Chapter Two: Manufacturers Profiles Chapter Four: Global Hypoxia Market Size by Regions Chapter Five: North America Hypoxia Market Revenue by Countries Chapter Six: Europe Hypoxia Market Revenue by Countries Chapter Seven: Asia-Pacific Hypoxia Market Revenue by Countries Chapter Eight: South America Hypoxia Market Revenue by Countries Find More Competitor in TOC with Profile Overview Share Growth Analysis @

Axxam Investments

1 Investments

Axxam has made 1 investments. Their latest investment was in Acousia Therapeutics as part of their Series A on December 12, 2016.

CBI Logo

Axxam Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/15/2016

Series A

Acousia Therapeutics

$2.6M

Yes

2

Date

12/15/2016

Round

Series A

Company

Acousia Therapeutics

Amount

$2.6M

New?

Yes

Co-Investors

Sources

2

Axxam Partners & Customers

10 Partners and customers

Axxam has 10 strategic partners and customers. Axxam recently partnered with leadXpro on October 10, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

10/28/2020

Partner

Switzerland

Strategic Alliance with Axxam and MercachemSyncom – leadXpro Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services.

Bresso , Villigen and Nijmegen 28 October 2020 Axxam SpA , leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets .

1

4/2/2020

Licensor

Ireland

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

DUBLIN & MILAN -- -- ERS Genomics Limited , which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier , and Axxam S.p.A. , a leading discovery biology company , today announced the signing of a license agreement granting Axxam S.p.A. access to ERS Genomics Limited ' CRISPR-Cas9 patent portfolio , to support Axxam S.p.A. 's integrated discovery service platform .

2

1/14/2020

Partner

Netherlands

ZoBio - Drug Discovery Technology Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms.

Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads .

1

8/1/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

2/1/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/28/2020

4/2/2020

1/14/2020

8/1/2017

2/1/2017

Type

Partner

Licensor

Partner

Partner

Partner

Business Partner

Country

Switzerland

Ireland

Netherlands

United States

United States

News Snippet

Strategic Alliance with Axxam and MercachemSyncom – leadXpro Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services.

Bresso , Villigen and Nijmegen 28 October 2020 Axxam SpA , leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets .

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

DUBLIN & MILAN -- -- ERS Genomics Limited , which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier , and Axxam S.p.A. , a leading discovery biology company , today announced the signing of a license agreement granting Axxam S.p.A. access to ERS Genomics Limited ' CRISPR-Cas9 patent portfolio , to support Axxam S.p.A. 's integrated discovery service platform .

ZoBio - Drug Discovery Technology Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms.

Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Axxam Team

3 Team Members

Axxam has 3 team members, including current Chief Executive Officer, Stefan Lohmer.

Name

Work History

Title

Status

Stefan Lohmer

Bayer HealthCare

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Stefan Lohmer

Subscribe to see more

Subscribe to see more

Work History

Bayer HealthCare

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Compare Axxam to Competitors

M
MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.

Oceanit Logo
Oceanit

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

D
DIATHEVA s.r.l.

DIATHEVA is an independent biotechnological company focused on the discovery, development and marketing of new and diagnostic products and on recombinant protein production under research grade, GLP and GMP conditions. Through its products and services DIATHEVA wishes to bring research into applications by cooperating in biological discovery with public and private research institutions.

I
ITER S.r.L

ITER S.r.l. offers its services to businesses and Public Administrations as a partner in developing customised projects and services "from the strategy to the secretariat. Since 1989 the company have been organising b2b events about topics such as:nn Electronic document and corporate information management -u003Eu003E OMATnOMAT: a edition programmennFront office -u003Eu003E VoiceComnnBiotechnologies -u003Eu003E BioforumnnNanotechnologies -u003Eu003E NanoforumnnIt has a database - consolidated and highly qualified - of over 110,000 names of people working in different sectors. It also has over 4,000 contacts - with the number growing constantly and rapidly - in the biotechnologies and nanotechnologies sectors;nnIt works successfully with businesses, associations, public bodies and authorities in the IT, Biotechnologies and Nanotechnologies sectors, spreading knowledge of solutions and services through the organisation of specialised seminars;nnIts aim is to be a meeting point between demand and supply in the CTI market through the publication of quarterly magazines iged.it (information on electronic document management) and VoiceCom news (focused on customer relations management);nnIt edits books, handbooks and does market research on topical issues, availing itself of qualified experts;nnIt disseminates knowledge of topics connected with CTI and biotechnologies through newsletters ITERnews and Bioforumnews.

C
Cambridge Biostability

Cambridge Biostability Limited (CBL) is a UK Biotechnology Company based on the Cambridge Science Park.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.